Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
65.24
+0.07 (0.11%)
Oct 24, 2024, 4:00 PM EDT - Market closed
Incyte Employees
Incyte had 2,524 employees as of December 31, 2023. The number of employees increased by 200 or 8.61% compared to the previous year.
Employees
2,524
Change (1Y)
200
Growth (1Y)
8.61%
Revenue / Employee
$1,528,135
Profits / Employee
$38,548
Market Cap
12.57B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2,524 | 200 | 8.61% |
Dec 31, 2022 | 2,324 | 230 | 10.98% |
Dec 31, 2021 | 2,094 | 321 | 18.10% |
Dec 31, 2020 | 1,773 | 317 | 21.77% |
Dec 31, 2019 | 1,456 | 89 | 6.51% |
Dec 31, 2018 | 1,367 | 159 | 13.16% |
Dec 31, 2017 | 1,208 | 228 | 23.27% |
Dec 31, 2016 | 980 | 288 | 41.62% |
Dec 31, 2015 | 692 | 104 | 17.69% |
Dec 31, 2014 | 588 | 107 | 22.25% |
Dec 31, 2013 | 481 | 68 | 16.46% |
Dec 31, 2012 | 413 | 45 | 12.23% |
Dec 31, 2011 | 368 | 121 | 48.99% |
Dec 31, 2010 | 247 | 26 | 11.76% |
Dec 31, 2009 | 221 | 9 | 4.25% |
Dec 31, 2008 | 212 | 16 | 8.16% |
Dec 31, 2007 | 196 | 10 | 5.38% |
Dec 31, 2006 | 186 | 9 | 5.08% |
Dec 31, 2005 | 177 | -9 | -4.84% |
Dec 31, 2004 | 186 | -268 | -59.03% |
Dec 31, 2003 | 454 | -37 | -7.54% |
Dec 31, 2002 | 491 | -94 | -16.07% |
Dec 31, 2001 | 585 | -737 | -55.75% |
Dec 31, 2000 | 1,322 | 214 | 19.31% |
Dec 31, 1999 | 1,108 | 241 | 27.80% |
Dec 31, 1998 | 867 | 191 | 28.25% |
Dec 31, 1997 | 676 | 218 | 47.60% |
Dec 31, 1996 | 458 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Fresenius Medical Care AG | 119,845 |
DaVita | 70,000 |
Dr. Reddy's Laboratories | 27,048 |
Solventum | 20,098 |
Smith & Nephew | 19,081 |
Exact Sciences | 6,600 |
BioMarin Pharmaceutical | 3,401 |
Sarepta Therapeutics | 1,314 |
INCY News
- 3 hours ago - Incyte Named One of Top 5 Companies on Science Magazine's 2024 Top Employers List - Business Wire
- 14 days ago - Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program - Business Wire
- 16 days ago - Incyte to Report Third Quarter Financial Results - Business Wire
- 16 days ago - Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 21 days ago - Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Multiple Late-Breaking Data Presentations from Incyte's Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress - Business Wire
- 5 weeks ago - Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease - PRNewsWire
- 5 weeks ago - Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets - Benzinga